Clinical Trial Update: Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 trial evaluating melphalan with total marrow irradiation and autologous stem cell transplantation for high-risk multiple myeloma has been withdraw…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Leukemia

Drugs mentioned

• Melphalan (Melphalan)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Plasma Cell Leukemia in Remission, Plasma Cell Myeloma | Phase 1, Phase 2 | Status: WITHDRAWN